Avant Diagnostics (OTC: AVDX) is a medical diagnostic technology company that specializes in large panel biomarker tests. Its first test, OvaDx®, is proposed for use in monitoring women previously diagnosed with ovarian cancer. OvaDx® is a sophisticated microarray-based test that measures the activation of the immune system in blood samples in response to ovarian tumor cell development. Pre-clinical research studies with OvaDx® indicate high sensitivity and specificity for all types and stages of ovarian cancer. Avant intends to sell or license OvaDx® and to expand its portfolio of diagnostic tests in the future. For more information, visit the company’s website at www.avantdiagnostics.com